Manipulating human dendritic cell phenotype and function with targeted porous silicon nanoparticles

Archive ouverte

Stead, Sebastian | Mcinnes, Steven J.P. | Kireta, Svjetlana | Rose, Peter | Jesudason, Shilpanjali | Rojas-Canales, Darling | Warther, David | Cunin, Frédérique | Durand, Jean-Olivier | Drogemuller, Christopher | Carroll, Robert | Coates, P. Toby | Voelcker, Nicolas

Edité par CCSD ; Elsevier -

International audience. Dendritic cells (DC) are the most potent antigen-presenting cells and are fundamental for the establishment of transplant tolerance. The Dendritic Cell-Specific Intracellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN; CD209) receptor provides a target for dendritic cell therapy. Biodegradable and high-surface area porous silicon (pSi) nanoparticles displaying anti-DC-SIGN antibodies and loaded with the immunosuppressant rapamycin (Sirolimus) serve as a fit-for-purpose platform to target and modify DC. Here, we describe the fabrication of rapamycin-loaded DC-SIGN displaying pSi nanoparticles, the uptake efficiency into DC and the extent of nanoparticle-induced modulation of phenotype and function. DC-SIGN antibody displaying pSi nanoparticles favourably targeted and were phagocytosed by monocyte-derived and myeloid DC in whole human blood in a time- and dose-dependent manner. DC preconditioning with rapamycin-loaded nanoparticles, resulted in a maturation resistant phenotype and significantly suppressed allogeneic T-cell proliferation.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion